Drug General Information (ID: DDI0MWL2IT)
Drug Name			Rubella virus vaccine		Drug Info		Siponimod		Drug Info
Drug Type		Vaccine				Small molecule
Therapeutic Class		Vaccine				Selective Immunosuppressants

Mechanism of Rubella virus vaccine-Siponimod Interaction (Severity Level: Major)
Antagonize the effect of vaccine/toxoid Click to Show/Hide Mechanism Graph
Drug Name		Rubella virus vaccine				Siponimod
Mechanism		Vaccine or toxoid				Immunosuppressive effects
Key Mechanism Factor 1
		Factor Name		Vaccine/toxoid
		Factor Description		The beneficial effects of the vaccine/toxinoid may be reduced, leading to a diminished or suboptimal immune response.
Mechanism Description		Antagonize the effect of Rubella virus vaccine when combined with Siponimod

Recommended Action
Management		The use of live attenuated vaccines should be avoided during and for up to 4 weeks after siponimod treatment, and siponimod should be paused 1 week prior to and until 4 weeks after a planned vaccination. Patients without a healthcare professional confirmed history of varicella or without documentation of a full course of vaccination against varicella-zoster virus (VZV) should be tested for antibodies to VZV before initiating treatment with siponimod. For antibody-negative patients, a full course of vaccination with varicella vaccine is recommended prior to treatment with siponimod. In patients who have recently been vaccinated, siponimod therapy should be postponed for 4 weeks to allow the full effect of vaccination to occur.

References
1	Cerner Multum, Inc. "Australian Product Information.".
2	Product Information. Mayzent (siponimod). Novartis Pharmaceuticals, East Hanover, NJ.